{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-053982","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.120828+00:00","generated_at":"2026-06-01T03:37:08.001388+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns","bullets":["Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.","Svetlana Lucas, Ph.D., appointed as Class III director effective June 18, 2024.","Lucas is Chief Business Officer at Scribe Therapeutics with 20+ years in biopharma strategy.","Received initial option grant of 15,000 shares at $23.19/share, vesting over 4 years.","Also serves on board of aTyr Pharma (Nasdaq: LIFE) and as advisor to Radar Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-053982","json":"https://secwatch.observer/filing/0001213900-24-053982.json","markdown":"https://secwatch.observer/filing/0001213900-24-053982.md","text":"https://secwatch.observer/filing/0001213900-24-053982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/ea0208074-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:37:08.001388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"932297e83c","claim":"Anna French resigned as Director at Jasper Therapeutics, Inc..","evidence_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","confidence":0.95},{"claim_id":"a571f3aa62","claim":"Svetlana Lucas was appointed as Class III Director at Jasper Therapeutics, Inc..","evidence_excerpt":"Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001213900-26-062334","ticker":"ACRG","company_name":"American Clean Resources Group, Inc.","filed_at":"2026-05-29T00:45:18+00:00","headline":"ACRG announces fractional executive transitions and new consultant for Nevada project","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062334","json":"https://secwatch.observer/filing/0001213900-26-062334.json","markdown":"https://secwatch.observer/filing/0001213900-26-062334.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/773717/000121390026062334/0001213900-26-062334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/773717/000121390026062334/ea0292686-8k_american.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"Michael Raabe Effective February 2, 2026, Michael Raabe transitioned from his role as fractional Chief Operating Officer of the Company to a fractional strategic operations and project management support role.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/773717/000121390026062334/0001213900-26-062334-index.htm"}},{"accession":"0001850902-26-000011","ticker":"TKNO","company_name":"Alpha Teknova, Inc.","filed_at":"2026-06-01T21:22:10+00:00","headline":"Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor","event_type":"leadership","sec_items":["5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001850902-26-000011","json":"https://secwatch.observer/filing/0001850902-26-000011.json","markdown":"https://secwatch.observer/filing/0001850902-26-000011.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/0001850902-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/tkno-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"On May 27, 2026, Irene Davis, a member of the Board of Directors (the “Board”) of Alpha Teknova, Inc. (the “Company”) and a member of the Nominating and Corporate Governance Committee, notified the Company of her intention not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “Meeting”) and to retire from the Board and all committees thereof, effective upon the date of the Meeting.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/0001850902-26-000011-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0002064307-26-000007","ticker":"LOGC","company_name":"ContextLogic Holdings Inc.","filed_at":"2026-06-01T20:15:17+00:00","headline":"ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002064307-26-000007","json":"https://secwatch.observer/filing/0002064307-26-000007.json","markdown":"https://secwatch.observer/filing/0002064307-26-000007.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/logc-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm"}},{"accession":"0001104659-26-068929","ticker":"VMI","company_name":"VALMONT INDUSTRIES INC","filed_at":"2026-06-01T20:15:13+00:00","headline":"Former CFO Thomas Liguori enters separation agreement; $4.9M retirement benefits","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068929","json":"https://secwatch.observer/filing/0001104659-26-068929.json","markdown":"https://secwatch.observer/filing/0001104659-26-068929.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/vmi-20260526x8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"Valmont Industries Inc. previously reported the appointment of John Schwietz as Valmont’s Executive Vice President and Chief Financial Officer and Corporate Secretary, effective April 8, 2026, to succeed Thomas Liguori.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm"}},{"accession":"0001104659-26-068891","ticker":"PSQH","company_name":"PSQ Holdings, Inc.","filed_at":"2026-06-01T20:02:28+00:00","headline":"PSQ Holdings SVP of People Michael Hebert resigns; severance of $137,500","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068891","json":"https://secwatch.observer/filing/0001104659-26-068891.json","markdown":"https://secwatch.observer/filing/0001104659-26-068891.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847064/000110465926068891/0001104659-26-068891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847064/000110465926068891/tm2616483d1_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"On May 26, 2026, Michael Hebert resigned from his position of Senior Vice President of People of PSQ Holdings, Inc. (the “Company”), effective May 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1847064/000110465926068891/0001104659-26-068891-index.htm"}},{"accession":"0000927089-26-000101","ticker":"MGNO","company_name":"Magnolia Bancorp, Inc.","filed_at":"2026-06-01T18:15:36+00:00","headline":"Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair","event_type":"leadership","sec_items":["5.02","5.07","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000927089-26-000101","json":"https://secwatch.observer/filing/0000927089-26-000101.json","markdown":"https://secwatch.observer/filing/0000927089-26-000101.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/0000927089-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/mban20260520_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm","comparable_excerpt":"On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2033615/000092708926000101/0000927089-26-000101-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}